Effects of Intracoronary Stem Cell Transplantation in Patients With Dilated Cardiomyopathy

A Randomized Comparative Study on the Efficacy of Intracoronary Infusion of Autologous Bone Marrow Mononuclear Cells and Mesenchymal Stem Cells in Patients With Dilated Cardiomyopathy

“…26) The beneficial effects of cell therapy in the setting of ischemic heart disease are not fully understood, and proposed mechanisms of action have included cardiomyocyte regeneration, 3,5,22) angiogenesis, [3][4][5]16,21,22,25) and inhibition of myocardial apoptosis and ventricular remodeling through paracrine factors of the infused cells. 3,14,21) The capacity of BMC to regenerate myocytes has been a matter of intense debate to date. Because severely reduced coronary flow reserve and impaired microvascular function are implicated in the pathogenesis and prognosis of nonischemic DCM, 9,10) Seth, et al 4) performed the first clinical study of intracoronary stem cell injection in patients with DCM and confirmed that cell therapy was safe and effective.…”

“…Because severely reduced coronary flow reserve and impaired microvascular function are implicated in the pathogenesis and prognosis of nonischemic DCM, 9,10) Seth, et al 4) performed the first clinical study of intracoronary stem cell injection in patients with DCM and confirmed that cell therapy was safe and effective. Since the pioneering work of Seth, et al 4,27) many groups have performed clinical trials and confirmed the effectiveness of this new therapy, 11,14) although these results have been disputed. 12,13) However, different stem cell subpopulations have different characteristics and plasticity: BMMC integrate almost all the BMC characteristics, can be easily harvested and manipulated, and are the cell type most studied and used in the clinical setting.…”

“…3,4) Intracoronary administration of autologous bone marrow stem cells (BMC) has proved to be safe and has shown significant improvement of cardiac function in the treatment of post-infarct and chronic ischemic models in both preclinical and clinical settings. [5][6][7][8] Because severely reduced coronary flow reserve and impaired microvascular function have been observed in patients with DCM, 9,10) several clinical studies have applied cell therapy to these patients, 4,[11][12][13][14] despite much controversy concerning the underlying mechanisms [3][4][5][14][15][16] and conflicting results from the procedure. 12,13) Most of these studies performed intracoronary infusion using either bone marrow mononuclear cells (BMMC), which are non-selected bone marrow stem cells, or bone marrow mesenchymal stem cells (BMSC).…”

Estado actual de la terapia con células madre en el tratamiento de las cardiopatías: An update

“…Se encuentra en 67 . En pacientes con miocardiopatía de etiología no isquémica, existe una experiencia más reducida [68][69][70][71][72][73][74][75] . El ensayo aleatorizado ABCD señaló un aumento significativo y persistente de la FEVI y mejora en la calidad de vida en pacientes con cardiopatía dilatada, tratados con BMMC autólogas en su seguimiento a 3 años 72 .…”

Interdisciplinary Approach at the Border Between Hematology and Cardiology

“…22 Vrtovec et al demonstrated that patients diagnosed with dilative cardiomyopathy and severe heart failure had low ventricular remodeling, a better exercise tolerance, and improved chances of survival and quality of life following intracoronary stem cell injection. 23 In conclusion, interdisciplinary medical teams formed by hematologists and cardiologists encounter various challenging situations that are not always faced by other kind of groups. Such challenges include the disputative characteristics of the medical vocational interdependence and expertise, planning and therapeutic decisionmaking processes, whilst offering a high quality medical care in complex clinical settings, for the complex patient with onco-hematological disorder with co-existing cardiac disease.…”